DE3631858C1 - Use of seeds of the neem tree as mother tincture for liquefying viscous mucus and viscous secretions - Google Patents
Use of seeds of the neem tree as mother tincture for liquefying viscous mucus and viscous secretionsInfo
- Publication number
- DE3631858C1 DE3631858C1 DE19863631858 DE3631858A DE3631858C1 DE 3631858 C1 DE3631858 C1 DE 3631858C1 DE 19863631858 DE19863631858 DE 19863631858 DE 3631858 A DE3631858 A DE 3631858A DE 3631858 C1 DE3631858 C1 DE 3631858C1
- Authority
- DE
- Germany
- Prior art keywords
- viscous
- mucus
- seeds
- mother tincture
- azadirachta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000003097 mucus Anatomy 0.000 title claims abstract description 20
- 235000013500 Melia azadirachta Nutrition 0.000 title claims abstract description 11
- 229940098465 tincture Drugs 0.000 title claims abstract description 6
- 230000028327 secretion Effects 0.000 title claims abstract description 5
- 240000005343 Azadirachta indica Species 0.000 title 1
- 244000237986 Melia azadirachta Species 0.000 claims abstract description 11
- 208000006673 asthma Diseases 0.000 claims abstract description 9
- 230000036515 potency Effects 0.000 claims abstract description 5
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims abstract description 4
- 230000001632 homeopathic effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000000621 bronchi Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000557821 Azadirachta Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Die Erfindung betrifft die Verwendung von Samen des Niem- Baumes als Urtinktur gemäß Anspruch 1.The invention relates to the use of seeds of the never Baumes as mother tincture according to claim 1.
Der Anspruch 2 hat eine vorteilhafte Ausgestaltung nach Anspruch 1 zum Gegenstand.The claim 2 has an advantageous embodiment Claim 1 on the subject.
Bisher ist es bekannt, daß Extrakte aus verschiedenen Organen des Niem-Baumes (Antelaea azadirachta, Synonym: Melia azadirachta L., Synonym: Azadirachta indica Juss.) pharmakologisch aktive Wirkstoffe enthalten, die je nach Ursprungsmaterial (Same, Fruchtfleisch, Blätter, Wurzel, Holz, Rinde) und Extraktionsbedingungen verschiedene therapeutische Wirkungskreise erschließen.So far it is known that extracts from different Organs of the Niem tree (Antelaea azadirachta, synonym: Melia azadirachta L., synonym: Azadirachta indica Juss.) contain pharmacologically active ingredients depending on Original material (seed, pulp, leaves, root, Wood, bark) and extraction conditions various open up therapeutic circles.
So ist es aus der DE-PS 31 32 655 bekannt, daß Heißwasser extrakte aus vorbehandelter Rinde des Niem-Baumes antineo plastische Aktivität haben. Extrakte nicht vorbehandelter Niem-Baum-Materialien mit hydrophilen Lösungsmitteln und/ oder heißem Wasser zur Verbesserung gastrointestinaler und hepatitischer Funktionen sind aus der japanischen offengelegten Patentanmeldung 10 124/78 bekannt. Hagers Handbuch der Pharmazeutischen Praxis, Springer Verlag, Berlin 1972, nennt unter dem Stichwort Antelaea azadirachta das Dekokt der Wurzelrinde des Niem-Baumes als Anthelmintikum. Dort wird auch über die Anwendung des Infuses als Fieber- und Bittermittel berichtet. Die Verwendung von Öl aus Niem-Samen in bakteriziden Seifen und Mundwässern sowie als Mittel gegen Hautkrank heiten wie Ekzeme, Furunkel usw., Prurigo, Lepra, Syphilis, Hämorrhoiden und Infektionen der Harnorgane wird im Auf satz von Gunther Berndt, Seifen Öle Fette Wachse Bd. 89, 1963, S. 894, angesprochen. So it is known from DE-PS 31 32 655 that hot water extracts from pretreated bark of the Niem antineo tree have plastic activity. Extracts not pretreated Niem Baum materials with hydrophilic solvents and / or hot water to improve gastrointestinal and hepatic functions are from Japanese published patent application 10 124/78 known. Hagers Handbook of Pharmaceutical Practice, Springer Verlag, Berlin 1972, names Antelaea under the keyword azadirachta the decoction of the root bark of the Niem tree as Anthelmintic. There is also about the application of the Infuses reported as a fever and bitter agent. The use of oil from Niem seeds in bactericidal Soaps and mouthwashes and as a remedy for skin diseases such as eczema, boils, etc., prurigo, leprosy, syphilis, Hemorrhoids and urinary tract infections are on the rise set by Gunther Berndt, soap oils fat waxes vol. 89, 1963, p. 894.
Aufgabe der vorliegenden Erfindung ist es, eine Möglich keit zur Verfügung zu stellen, die schnelle Verflüssigung von zähem Schleim und dickflüssigen Sekreten, insbesondere bei Asthma bronchiale, zu erreichen.The object of the present invention is one possible ability to provide the fast liquefaction of viscous mucus and viscous secretions, especially in bronchial asthma.
Bei Asthmatikern bildet sich der Schleim in den Bronchien hauptsächlich durch die Verengung der Bronchialmuskulatur und durch bisher noch nicht völlig erforschte Stoffwechselstörungen. Zum Beispiel bei allergischem Asthma verengt sich die Bronchialmuskulatur, wodurch die Verschleimung verstärkt wird. Die zunehmende Verschleimung verstärkt wiederum die allergische Reaktion. Der dann nicht mehr abfließende Schleim ist ein idealer Nährboden für infektiöse Erkrankungen.In asthmatics, the mucus forms in the bronchi mainly due to the narrowing of the bronchial muscles and by not yet fully researched Metabolic disorders. For example with allergic Asthma constricts the bronchial muscles, causing the Mucilage is amplified. The increasing mucus in turn increases the allergic reaction. The one then phlegm that no longer drains is an ideal breeding ground for infectious diseases.
Die Lösung der Aufgabe ist durch die Ansprüche 1 und 2 ge kennzeichnet.The solution to the problem is ge by claims 1 and 2 indicates.
Die Wirkung der hier beschriebenen Verwendung von Samen des Niem-Baums besteht darin, daß der Schleim in relativ kurzer Zeit verflüssigt wird und die Vermehrung von Krankheitserregern verhindert oder zumindest aber stark eingedämmt wird. Der kranke Mensch kann wesentlich flüssigeren Schleim leichter abhusten oder auswerfen und wird bei richtiger Dosierung schon am 1. oder 2. Tag schleimfrei sein. Dadurch ist der Kreislauf zwischen Asthma bronchiale allergischer Natur und Infektasthma gestoppt.The effect of the use of seeds described here of the Niem tree is that the mucus in relative is liquefied in a short time and the multiplication of Pathogens prevented or at least strong is contained. The sick person can do essential easier to cough up or eject more liquid mucus and with the right dosage, it will be on the 1st or 2nd day be slimy. This is the cycle between Bronchial asthma of an allergic nature and infectious asthma stopped.
Die erfindungsgemäße Verwendung von Samen des Niem-Baumes verflüssigt Schleim in den Atemwegen, angefangen von der Nase mit Nasennebenhöhlen bis zu den Bronchien. Durch die Verflüssigung des zähen Schleims und der dick flüssigen Sekrete lösen sich Verstopfungen oder Ein engungen in den Atmungsorganen auf.The use according to the invention of seeds of the Niem tree liquefies mucus in the airways, starting from the Nose with sinuses up to the bronchi. By liquefying the viscous mucus and the thick Liquid secretions loosen blockages or in constrictions in the respiratory organs.
Die Verwendung der Urtinktur erfolgt als solche oder in homöopathischen Potenzen, vorzugsweise D3. Sie umfaßt auch die üblichen anderen galenischen Zubereitungen z. B. in Kapseln, Tabletten, Cremes, Salben oder Sprays.The mother tincture is used as such or in homeopathic potencies, preferably D3. It includes also the usual other pharmaceutical preparations such. B. in capsules, tablets, creams, ointments or sprays.
Die Wirkungsweise soll an dem nachstehenden Beispiel exemplarisch deutlich gemacht werden.The mode of operation should be based on the example below be made clear by way of example.
Eine Testperson, die seit 6 Jahren an allergischem Asthma leidet, (eine Desensibilisierung ist nicht möglich, da sich der Kontakt mit den auslösenden Stoffen nicht vermeiden läßt) leidet, durch die allergischen Anfälle ausgelöst, auch an einer ständigen Verschleimung der Bronchien und den damit möglichen infektiösen Erkrankungen, wobei der Schleim besonders zäh ist. Durch diese Verschleimung ist eine ständige Infektion gegeben, die die asthmatischen Beschwer den verstärken. Damit ist eine sehr häufige Verstopfung der Nasenhöhlen verbunden.A test subject who has had allergic asthma for 6 years suffers (desensitization is not possible because do not avoid contact with the triggering substances causes allergic seizures, also due to a permanent mucous membrane of the bronchi and the thus possible infectious diseases, whereby the mucus is particularly tough. Because of this mucus is one given constant infection that the asthmatic complaint reinforce that. So constipation is very common connected to the nasal cavities.
Für diesen Patienten wurde ein Auszug aus dem Samen des Niem-Baumes in der homöopathischen Potenz D3 in Tropfen form hergestellt. Der Patient begann mit der erstmaligen Einnahme von 8 Tropfen und verspürte bereits nach 1 Stunde deutliche Abnahme des Schleims in den Bronchien und in den Nasenhöhlen, weil er sich zu verflüssigen begann. Daraufhin hat die Testperson alle 4 Stunden immer 8 Tropfen eingenom men. Bereits am 2. Tag konnte eine normale Konsistenz des Bronchialschleimes festgestellt werden und die Nasenneben höhlen hatten normale Feuchtigkeit. Das hatte zur Folge, daß die Testperson ganz normal atmen konnte, solange sie nicht unter einem allergischen Anfall zu leiden hatte.An extract from the semen of the Niem-Baum's homeopathic potency D3 in drops shape. The patient started with the first Taking 8 drops and already felt after 1 hour significant decrease in mucus in the bronchi and in the Nasal cavities because it started to liquefy. Thereupon the test person always took 8 drops every 4 hours men. A normal consistency of the Bronchial mucus can be found and the nasal passages caves had normal moisture. As a result that the test person could breathe normally as long as they had no allergic seizure.
Zur Bekämpfung der Atemnot setzt die Testperson ein Dosier aerosol ein, durch das vor Einnahme des erfindungsgemäßen Medikaments zwar eine Entspannung der Bronchialmuskulator erreicht wurde, die aber durch die Verschleimung in ihrer Wirksamkeit behindert wurde. The test subject uses a dose to combat shortness of breath aerosol, through which before taking the invention The drug relaxes the bronchial muscle was achieved, but through the mucus in her Effectiveness was hindered.
Das Dosieraerosol mußte wiederholt eingesetzt werden. Die Wiederherstellung einer relativ normalen Atmung dauerte 1,5 bis 2 Stunden. Durch die zusätzliche Einnahme des er findungsgemäßen Medikaments bewirkte das Dosieraerosol inerhalb von 15 bis 20 Minuten eine normale Atmung. Die Atmung war durch den verflüssigten Schleim mit der Atmung eines gesunden Menschen vergleichbar. Die Testperson kannte solch normale Atmung nur nach hoher Cortisongabe.The metered dose aerosol had to be used repeatedly. The Restoring relatively normal breathing took 1.5 to 2 hours. By taking the he Drug according to the invention caused the metered dose aerosol normal breathing within 15 to 20 minutes. The Breathing was due to the liquefied mucus with the breath comparable to a healthy person. The test person knew such normal breathing only after high cortisone administration.
Die Wirkung der eingenommenen Tropfen hielt bei der Test person anfangs nur 4-5 Stunden an. Danach war wieder eine Zunahme des Bronchialschleimes festzustellen. Nach regel mäßiger Einnahme wurde tagsüber nach Ablauf von 4 Wochen eine Wirkung bis zu 8 Stunden beobachtet.The effect of the drops ingested during the test person initially only 4-5 hours. Then there was another Determine increase in bronchial mucus. According to rule moderate intake was taken during the day after 4 weeks an effect observed up to 8 hours.
Bei Absetzen des Medikaments waren keinerlei Entzugser scheinungen festzustellen. Es scheinen auch keine anderen Abhängigkeiten entstanden zu sein. Bei der besonders em pfindlichen Testperson war lediglich ein ganz leichtes Augenbrennen festzustellen, daß durch die Einnahme von Vitamin A behoben werden konnte.When the drug was discontinued, there were no withdrawals determine phenomena. There don't seem to be any others Dependencies have arisen. With the particularly em The sensitive test person was just a very easy one Burning eyes notice that by taking Vitamin A could be fixed.
Neben der Beseitigung des Bronchialschleimes hatten die Tropfen die Wirkung, auch die Nase und die Nasenneben höhlen von dickflüssigen Schleimen, hervorgerufen durch Infekte, zu befreien und die Sekretion der Nasenschleim häute zu normalisieren.In addition to removing the bronchial mucus, they had The effect drops, including the nose and nasal passages hollow out viscous mucus caused by Infections, rid and secretion of the nasal mucus normalize skins.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863631858 DE3631858C1 (en) | 1986-09-19 | 1986-09-19 | Use of seeds of the neem tree as mother tincture for liquefying viscous mucus and viscous secretions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863631858 DE3631858C1 (en) | 1986-09-19 | 1986-09-19 | Use of seeds of the neem tree as mother tincture for liquefying viscous mucus and viscous secretions |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3631858C1 true DE3631858C1 (en) | 1988-05-05 |
Family
ID=6309902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19863631858 Expired DE3631858C1 (en) | 1986-09-19 | 1986-09-19 | Use of seeds of the neem tree as mother tincture for liquefying viscous mucus and viscous secretions |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE3631858C1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3809427A1 (en) * | 1988-03-21 | 1989-10-05 | Klaus Hegelich | Use of seeds of the neem tree for the prophylaxis and therapy of viral infections |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3132655C2 (en) * | 1980-08-19 | 1986-06-12 | Terumo Corp., Tokio/Tokyo | Hot water extract from the bark of the Nim tree |
-
1986
- 1986-09-19 DE DE19863631858 patent/DE3631858C1/en not_active Expired
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3132655C2 (en) * | 1980-08-19 | 1986-06-12 | Terumo Corp., Tokio/Tokyo | Hot water extract from the bark of the Nim tree |
Non-Patent Citations (3)
Title |
---|
BERNDT G.: Seifen-Öle-Fette-Wachse, 89, Nr.26, 894 (1963) * |
LIST P.H.: Höhrhammer L., Hagers Handbuch der Pharmazeutischen Praxis, Berlin 1976, Springer Verlag, Bd.V, S.753-755 * |
LIST P.H.: Hörhammer L.,Hagers Handbuch der Pharmazeutischen Praxis, Berlin 1972, Springer Verlag, Bd.III, S.107-108 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3809427A1 (en) * | 1988-03-21 | 1989-10-05 | Klaus Hegelich | Use of seeds of the neem tree for the prophylaxis and therapy of viral infections |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1073445B1 (en) | Substance mixture for topical application comprising olive oil and honey | |
DE60028377T2 (en) | OREGANO BASED COMPOSITION | |
Rout et al. | Natural green alternatives to psoriasis treatment–a review | |
Konkon et al. | Medicinal plants used for treatment of diabetes by traditional practitioners in the markets of Abidjan district in Côte d’Ivoire | |
EP0668768B1 (en) | Composition for controlling dermatomycoses and their agents, as well as transpiration and bodily odours | |
Barmak et al. | Effect of Aloe vera extract on ovaries development in during gestational age of 18 day embryo of diabetic rats | |
DE3631858C1 (en) | Use of seeds of the neem tree as mother tincture for liquefying viscous mucus and viscous secretions | |
KR102062230B1 (en) | Cosmetic composition with skin soothing effect comprising vitamin tree extract, and manufacturing method thereof | |
WO2005076750A2 (en) | A novel synergistic herbal formulation for diabetes cure | |
DE3809427A1 (en) | Use of seeds of the neem tree for the prophylaxis and therapy of viral infections | |
DE202007002146U1 (en) | Herbal composition, useful to treat, e.g. cancer, comprises extracts of Ginseng flowers and roots, Astragalus, Atractylodes, Angelica, Citrus reticulata, Bupleurum chinenis, sweet woodrose and Cimicifuga root | |
Pandey | A glimpse into the Indian traditional medicine with special reference to use of Hemidesmus indicus in Southern India: A review | |
Ojewale et al. | HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITIES OF ETHANOLIC ROOTS EXTRACT OF CROSSOPTERYX FEBRIFUGA IN ALLOXAN-INDUCED DIABETIC RATS. | |
Fonseka et al. | A review on the therapeutic potentials of Ocimum sanctum Linn: in the management of diabetes Mellitus (Madhumeha) | |
DE4244754C2 (en) | Combating the pathogens of dermatomycoses in clothing | |
Muhammad et al. | Effects of petroleum ether and n-hexane extracts of Globemetula brauni on glucose, lipids and some biochemical parameters of diabetic rats. | |
Chandrasekar et al. | Laxative a herbal remedy for relieving constipation | |
JP7523889B2 (en) | Pharmaceutical composition for improving activity level | |
DE4237551C1 (en) | Use of a plant-based composition to combat dermatomycoses | |
Khan et al. | GULE NILOFER (Nymphaea alba) AN INFLUENTIAL DRUG IN UNANI MEDICINE: A REVIEW WITH IMMENCE THERAPEUTIC POTENTIAL AND PHYTO-PHARMACOLOGICAL PERSPECTIVE | |
Nagar et al. | Antihyperglycemic and antihyperlipidemic activity of root extracts of Erythrina variegata in stroptozotocin induced diabetic rats | |
Balkrishna et al. | Nature’s Signature in Ayurveda with an Ethnopharmacological Approach: A Narrative Review | |
El Yahyaoui El Drissi et al. | Risk of intoxication the plants more used in herbal medicine in Morocco | |
DE60213522T2 (en) | Combination of Arnica, Ruscus and Menthol | |
Rahman et al. | Anti diabetic medicinal plants used in Bangladesh for diabetes mellitus: A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8100 | Publication of the examined application without publication of unexamined application | ||
D1 | Grant (no unexamined application published) patent law 81 | ||
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: HEGELICH, DORIS, 58636 ISERLOHN, DE |
|
8381 | Inventor (new situation) |
Free format text: HEGELICH, KLAUS, 58636 ISERLOHN, DE |
|
8339 | Ceased/non-payment of the annual fee |